ESMO-Asia Oral IMpower150: an exploratory analysis of efficacy outcomes in patients with EGFR mutations

Nov 09, 2018 by [Daura MELLA - ESMO]

IMpower150 is a global 1L Phase III study evaluating the efficacy and safety of atezolizumab in combination with chemotherapy with or without bevacizumab in patients with stage IV or recurrent metastatic non-squamous NSCLC, including those with EGFR or ALK genomic alterations. The efficacy and safety of atezo and/or bev with chemo in patients with EGFR mutations were further analysed in this study.

Current View

Receive this presentation and more content via email